Japanese pharmaceutical company Takeda released, on Monday night (5), a note informing that it will not sign new contracts with private clinics or with states and municipalities to sell dengue vaccines. The company stated that, due to the alarming data on the disease in Brazil, it is focused on serving the Ministry of Health as a priority.
“This decision plans to support the Ministry of Health in its purpose of promoting access to the dengue vaccine in a comprehensive and free way for the Brazilian population”, says the note.
The Qdenga vaccine will begin to be distributed to the Unified Health System (SUS) this week, according to the Ministry of Health. The 521 municipalities that receive the doses must organize the immunization schedule. As there are not enough doses for the entire country, the municipalities chosen were those that make up 37 health regions that, according to the ministry, are considered endemic for the disease.
The public that will receive the vaccine will be made up of children and adolescents aged 10 to 14 years, the age group that has the highest number of hospitalizations due to dengue, after elderly people, a group for which the vaccine has not been released by the National Health Surveillance Agency ( Anvisa).
Takeda explained that it will comply with the contracts already signed and guaranteed the delivery of the necessary doses so that people who took the first dose of the vaccine on the private network complete their vaccination schedule — depending on the need to apply two doses three months apart — but new contracts will not be closed.
The pharmaceutical company also said that it is committed to supporting the health authorities, and that it has turned all its efforts to meeting the demand of the Ministry of Health, in accordance with the vaccination strategy defined by the Department of the National Immunization Program (DPNI).
6.6 million doses will be delivered for the year 2024 and another 9 million doses are expected to be delivered for the year 2025. “We are looking for all possible solutions to increase the number of doses available in the country, and we will not measure efforts to achieve this”, says Takeda.
According to the company, a strategic plan to increase global supply of the vaccine has been put together. The goal is to reach 100 million doses per year by 2030, including the inauguration of a new global center dedicated to vaccine production, in Singen, Germany, scheduled to be ready in 2025.
Takeda's headquarters in Brazil is also seeking partnerships with national public laboratories to accelerate vaccine production capacity.
Source: CNN Brasil
I’m James Harper, a highly experienced and accomplished news writer for World Stock Market. I have been writing in the Politics section of the website for over five years, providing readers with up-to-date and insightful information about current events in politics. My work is widely read and respected by many industry professionals as well as laymen.
